Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
7
×
life sciences
national blog main
biotech
boston
national top stories
new york blog main
san diego blog main
new york top stories
san diego top stories
san francisco blog main
drugs
dyne therapeutics
fda
myotonic dystrophy type 1
rare disease drugs
rare diseases
third rock ventures
abbvie
akcea therapeutics
allergan
ally bridge group
alzheimer's disease
antisense oligonucleotide
anylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
benzodiazepines
big data analytics
biogen
biotech ipos
blackrock
blackstone group
blackstone life sciences
bluebird bio
blueprint medicines
What
genetic
7
×
medicines
drug
ipo
new
rare
ago
approved
biotech
company
diseases
dyne
experimental
fda
million
muscle
oks
raised
research
therapeutics
abbvie
aims
akcea
alliance
alnylam
amyloidosis
analysis
attr
available
backed
battle
bio
biotechs
bring
brings
cancer
cause
ceo
considering
data
Language
unset
Current search:
genetic
×
" clinical trials "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues